Restaurants & Bars Dining out has also slowed down
A research article on the safety, compatibility and effectiveness of the glucagon receptor-GLP- 1 receptor dual agonist Survodutide in obesity management
Recurrent moderate hypoglycemia accelerates the progression of Alzheimers disease through impairment of the TRPC6/GLUT3 pathway
Persons with pre-existing cardiovascular conditions or those taking medications affecting blood pressure should exercise caution and confer with a medical service specialist before using this peptide
The company declared a boost in its R&D investment to $4.4 billion in 2022
Other diabetes medication classes offer alternatives if GLP-1 therapy proves unsuitable: SGLT2 inhibitors (such as dapagliflozin or empagliflozin) provide cardiovascular and renal benefits without affecting gastric emptying, though require adequate renal function and carry risks of genital infections and diabetic ketoacidosis DPP-4 inhibitors (such as sitagliptin) work on the incretin system but with less pronounced gastrointestinal effects note these should not be combined with GLP-1 receptor agonists Traditional agents including metformin, sulfonylureas, or insulin may be appropriate depending on individual circumstances Any medication change should be made in consultation with your diabetes specialist or GP, considering your overall glycaemic control, cardiovascular risk profile, and treatment goals, in line with NICE NG28 guidance